I would agree with a meta analysis, but for now I think Andreas’ comments are the most scientifically valid and that 3 weekly carboplatin/taxol should remain the “reference” arm  for  studies where the aim is to assess superiority of an alternative regimen.  However, it need not always be the “control” arm.  If we consider that the MITO7 regimen is likely to remain in clinical practise then it seems a reasonable option for it to be a control arm, particularly for studies where the primary focus is QOL or in studies involving older/frailer patients.  I think the latter studies are an important unmet need.